Search Results - "Slootbeek PHJ"

Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis.

Authors: Russo, Luigi Giacobini, Erika Lentini, Nicolò et al.

Source: PLoS Medicine. 6/9/2026, Vol. 23 Issue 6, p1-30. 30p.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Authors: Turco F Gillessen S Salfi G et al.

Source: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2026 May 29. Date of Electronic Publication: 2026 May 29.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Authors: Kloots ISH Slootbeek PHJ Tolmeijer SH et al.

Corporate Authors: Kloots ISH Slootbeek PHJ Tolmeijer SH et al.

Source: British journal of cancer [Br J Cancer] 2026 Jan; Vol. 134 (2), pp. 306-316. Date of Electronic Publication: 2025 Oct 31.

Publication Type: Journal Article; Observational Study

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Differential Response to ¹⁷⁷Lu-PSMA-617 in Patients with Tumor Suppressor Gene–Mutated Metastatic Castration-Resistant Prostate Cancer.

Authors: Pepin, Abigail Doucette, Abigail Narayan, Vivek K. et al.

Source: Journal of Nuclear Medicine. Jun2026, Vol. 67 Issue 6, p926-928. 3p.

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Authors: Slootbeek PHJ Luna-Velez MV Privé BM et al.

Source: Theranostics [Theranostics] 2024 Aug 01; Vol. 14 (12), pp. 4555-4569. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.

Authors: Privé, Bastiaan M. Janssen, Marcel J. R. van Oort, Inge M. et al.

Source: Trials. 11/4/2021, Vol. 22 Issue 1, p1-4. 4p.

PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.

Authors: Slootbeek PHJ Overbeek JK Ligtenberg MJL et al.

Source: Cancer letters [Cancer Lett] 2023 Nov 28; Vol. 577, pp. 216367. Date of Electronic Publication: 2023 Sep 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE

[¹⁷⁷Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study.

Authors: Satapathy, Swayamjeet Yadav, Madhav Prasad Ballal, Sanjana et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2024, Vol. 51 Issue 8, p2495-2503. 9p.

Prostate cancer and genetic contributions.

Authors: Chou, Wesley H. Chalker, Cameron Sokolova, Alexandra O. et al.

Source: Andrology. Jul2025, Vol. 13 Issue 5, p1149-1157. 9p.

Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Authors: Yanagisawa T Matsukawa A Rajwa P et al.

Source: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2026 Jun; Vol. 29 (2), pp. 258-270. Date of Electronic Publication: 2025 Oct 08.

Publication Type: Journal Article; Systematic Review; Meta-Analysis; Review

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE

Clinical approaches to overcome PARP inhibitor resistance.

Authors: Zou, Yutian Zhang, Hanqi Chen, Pangzhou et al.

Source: Molecular Cancer. 5/30/2025, Vol. 24 Issue 1, p1-25. 25p.

CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy.

Authors: Younis NK Al-Hussainy AF Jyothi SR et al.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 Jul; Vol. 28 (7), pp. 2523-2549. Date of Electronic Publication: 2026 Feb 01.

Publication Type: Journal Article; Review

Journal Info: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.

Authors: Vlachos G Moser T Lazzeri I et al.

Source: British journal of cancer [Br J Cancer] 2026 Mar; Vol. 134 (6), pp. 949-960. Date of Electronic Publication: 2026 Jan 09.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study.

Authors: Hyväkkä, Anniina Kääriäinen, Okko‐Sakari Utriainen, Tapio et al.

Source: Cancer Medicine. Feb2023, Vol. 12 Issue 4, p4064-4076. 13p.

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.

Authors: Murthy, Vishnu Ludwig, Vinicius Gafita, Andrei et al.

Source: Journal of Nuclear Medicine. Jun2025, Vol. 66 Issue 6, p833-838. 6p.

DNA/RNA-based electrochemical nanobiosensors for early detection of cancers.

Authors: Mikaeeli Kangarshahi, Babak Naghib, Seyed Morteza Rabiee, Navid

Source: Critical Reviews in Clinical Laboratory Sciences. Sep2024, Vol. 61 Issue 6, p473-495. 23p.

Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer".

Authors: van der Doelen MJ Slootbeek PHJ Mehra N

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Feb; Vol. 144, pp. 395-396. Date of Electronic Publication: 2020 Dec 25.

Publication Type: Letter; Comment

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.

Authors: van der Doelen MJ Isaacsson Velho P Slootbeek PHJ et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 16-24. Date of Electronic Publication: 2020 Jul 04.

Publication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.

Authors: Bent EH Morris MJ

Source: Current oncology reports [Curr Oncol Rep] 2025 Oct; Vol. 27 (10), pp. 1170-1184. Date of Electronic Publication: 2025 Aug 27.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE

Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?

Authors: Slootbeek, Peter H. J. Tolmeijer, Sofie H. Mehra, Niven et al.

Source: Critical Reviews in Clinical Laboratory Sciences. May2024, Vol. 61 Issue 3, p178-204. 27p.